Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer

Next Previous
X
Search
Trial Profile

Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 25 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anastrozole (Primary) ; Carboplatin (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin liposomal (Primary) ; Epirubicin (Primary) ; Exemestane (Primary) ; Gemcitabine (Primary) ; Letrozole (Primary) ; Paclitaxel (Primary) ; Pertuzumab (Primary) ; Tamoxifen (Primary) ; Trastuzumab (Primary) ; Trastuzumab emtansine (Primary)
  • Indications Carcinoma; Early breast cancer
  • Focus Therapeutic Use
  • Acronyms ADAPT

    • Most Recent Events

    • 20 Nov 2024 Planned End Date changed from 1 Oct 2024 to 1 Dec 2024.
    • 23 Mar 2023 Status changed from recruiting to active, no longer recruiting.
    • 11 Dec 2020 According to a EXACT Sciences Corporation media release, the trial used Oncotype DX Breast Recurrence Score test to help guide treatment decisions in breast cancer patients with high clinical risk, including those with node-positive disease.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top